GlassScriptPhysician profile
Lorri Hinton
NPI 1366054389
$2,065.45
in general payments reported to CMS, 2019-2025
29 companies · $1,123 in 2025
The $1,123 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $38.11 · 2023: $53.76 · 2024: $641 · 2025: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.75 |
| Education | $194.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $348.46 | 2021-2025 | Enhertu, Vanflyta, Datroway |
| Novartis Pharmaceuticals Corporation | $294.01 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $267.41 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $175.83 | 2025 | Rybrevant, Erleada |
| E.R. Squibb & Sons, L.L.C. | $105.70 | 2021-2025 | Opdivo |
| Eisai INC. | $74.12 | 2024-2025 | |
| Acrotech Biopharma INC. | $71.01 | 2024-2025 | Beleodaq |
| Takeda Pharmaceuticals U.S.A., INC. | $60.60 | 2024-2025 | Iclusig, Fruzaqla |
| Adc Therapeutics America, INC. | $56.51 | 2024-2025 | |
| Exelixis INC. | $53.00 | 2024-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $50.32 | 2024-2025 | Ojjaara |
| Rigel Pharmaceuticals, INC. | $49.13 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Jazz Pharmaceuticals INC. | $43.88 | 2024 | |
| Lilly USA, LLC | $43.87 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Stemline Therapeutics INC. | $40.79 | 2025 | Orserdu |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $38.43 | 2024-2025 | Tazverik, Onivyde |
| Astrazeneca Pharmaceuticals LP | $35.05 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $33.01 | 2024-2025 | Qinlock, Romvimza |
| Genzyme Corporation | $32.55 | 2021 | |
| Aveo Pharmaceuticals, INC. | $27.18 | 2024-2025 | |
| Myovant Sciences INC. | $23.93 | 2022 | |
| Genmab U.S., INC. | $23.88 | 2024 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.88 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $18.69 | 2024 | Libtayo |
| Incyte Corporation | $18.21 | 2025 | Jakafi, Niktimvo |
| Geron Corporation | $16.70 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $14.95 | 2024 | Xpovio |
| Amgen INC. | $13.72 | 2021 | |
| Coherus Oncology, INC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorri Hinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.